Wednesday, October 8, 2025

Latest

Raymond James: Cronos Financials A “Relative Non-Event”

On February 26th, Cronos Group (TSX: CRON) (NASDAQ: CRON) reported fourth quarter and full year financial results. The company reported fourth quarter total revenue of C$17 million, a 50% increase quarter over quarter, while also reporting negative gross margins of 87% or -C$14.9 million. Adjusted EBITDA came in at -C$53.1 million. For the full year, Cronos reported net revenues of $46.7 million, an almost 100% increase year over year; adjusted EBITDA came in at -C$147.3 million for the full year.

Cronos Group currently has 11 analysts covering the company with a weighted 12-month price target of C$9.69. This is slightly up from the average before the results, which was C$8.74. Two analysts have buy ratings, seven analysts have hold ratings, while two analysts have strong sells on the company.

In Raymond James’ note to investors, they reiterate their C$11 price target and outperform 2 rating. Rahul Sarugaser, Raymond James’ analyst, headlines, “4Q20: Big Revenue Beat, EBITDA Miss | New Dist. Deals, CBG Biosynthesis on Track for 3Q21.”

Although they call the quarterly and full year results a “relative non-event,” Cronos beat Raymond James’ revenue estimate of C$14 million, while EBITDA swung into a large miss with their estimate being -C$26.3 million.

Sarugaser says that the revenue beat was mainly driven by strong growth in the Canadian adult-use segment and sales to Israel, which was us 39% quarter over quarter. In an exciting turnaround, Cronos’ U.S CBD sales more than doubled quarter over quarter and had a 52% gross margin. The growth was driven by the Lord Jones CBD branded product sales.

Onto Raymond James’ favourite topic, Cronos’ partnership with Ginkgo Biosynthesis. They reiterate management’s third-quarter 2021 date, for when the company expects to commercialize cannabinoids derived from fermentation. Sarugaser writes, “CRON is one of the companies we believe will change the cannabinoid product landscape through its longstanding commitment to innovation paired with its (and Altria’s) significant resources.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Haywood Raises Nevada Copper Price Target After Debt Extension

On October 12th, Nevada Copper Corp. (TSX: NCU) announced that it has entered into an...

Saturday, October 16, 2021, 01:05:00 PM

Canaccord Reiterates Columbia Care As A Cannabis Top Pick

Columbia Care (NEO: CCHW) reported its first quarter financial results on May 17th. The company...

Thursday, May 20, 2021, 04:41:00 PM

Shopify: Canaccord Raises Price Target To $1,450 Off Back Of Strong Earnings

Shopify (NYSE: SHOP) reported second-quarter financials on July 28th. The company is keeping the US...

Friday, July 30, 2021, 04:32:00 PM

Green Thumb: Canaccord Lowers Price Target After Earnings Missed Estimates

On November 10th, Green Thumb Industries (CSE: GTII) reported its third quarter financial results. The...

Tuesday, November 16, 2021, 03:27:00 PM

Rogers: “Minority Shareholders Need Closure Not Chaos”

Rogers Communications (TSX: RCI) continues to be the centre of attention within the Canadian markets,...

Sunday, October 31, 2021, 04:56:00 PM